GO
Loading...

Endo Health Solutions Inc

More

  • *Endo offers $33.25/ share for Auxilium. Oct 9- Endo International Plc brought a successful end to its month-long pursuit of Auxilium Pharmaceuticals Inc, with the smaller rival choosing a sweetened offer over its agreement to buy Canadian eye-drug maker QLT Inc.. "Endo recognizes the value inherent to Xiaflex, given the drug's potential in multiple additional...

  • NEW YORK, Oct 9- U.S. stock index futures pointed to a lower Wall Street open on Thursday, with earlier gains erased as concerns about global growth spurred investors to take profit following a massive advance in the previous session. The third-quarter earnings season got off to a strong start, with both Alcoa Inc and PepsiCo Inc rallying in premarket trading...

  • Oct 9- Auxilium Pharmaceuticals Inc agreed to be bought by Endo International Plc for $1.67 billion and terminated its deal to buy Canadian eye-drug maker QLT Inc.. Endo moved its tax domicile to Ireland from Pennsylvania last year when it bought Canadian drugmaker Paladin Labs Inc.. Citi is Endo's financial adviser and Sullivan& Cromwell LLP is its legal...

  • NEW YORK, Oct 9- Alcoa Inc and PepsiCo Inc were among Thursday's biggest premarket movers, with both rallying on strong results. Aluminum maker Alcoa jumped 1.6 percent to $16.32, a day after its third-quarter earnings beat expectations on higher aluminum prices and lower costs. The results contributed to a positive tone on Wall Street as Alcoa was one of the...

  • Oct 9- Endo International Plc said it would buy Auxilium Pharmaceuticals Inc in a deal valued at $2.6 billion, including the repayment and assumption of debt. Endo's offer of $33.25 per share represents a premium of about 12 percent to Auxilium's Wednesday close and is higher than Endo's previous offer of $28.10. As part of the deal, Auxilium terminated its...

  • Oct 3- A jury award of $73.4 million to a woman who said she was injured by a Boston Scientific Corp transvaginal mesh device has been cut to $34.6 million, thanks to a Texas law that caps how much companies must pay in punitive damages. Last month, jurors in Dallas found Boston Scientific liable for selling a defective Obtryx sling that was implanted in plaintiff...

  • Sept 22- Auxilium Pharmaceuticals Inc said its board had determined that Endo International Plc's $2.2 billion takeover offer "significantly undervalues" the company, but left the door open for talks on a possible deal.

  • Sept 22- Auxilium Pharmaceuticals Inc said its board had determined that Endo International Plc's offer "significantly undervalues" the company. Auxilium said in June that it would buy QLT for $346 million, in a deal aimed at cutting its tax bill by moving its headquarters to lower-tax British Columbia, Canada.

  • Sept 22- Auxilium Pharmaceuticals Inc said its board had determined that Endo International Plc's offer "significantly undervalues" the company. Endo made an unsolicited offer last week to buy Auxilium for about $2.2 billion. Auxilium's board also reiterated on Monday that it backed the company's offer to buy Canadian eye drug maker QLT Inc.

  • The drug, developed by Vivus Inc, is marketed in the United States and Canada by Auxilium Pharmaceuticals Inc. Vivus' stock was up about 13 percent at $4.40 in afternoon trading.

  • The drug was developed by Auxilium Pharmaceuticals Inc and Vivus Inc.. Vivus owns the worldwide development and commercial rights to Stendra for use in sexual dysfunction, with the exception of certain Asian countries in the Pacific Rim.

  • The drug, developed by Vivus Inc, is marketed in the United States and Canada by Auxilium Pharmaceuticals Inc. Vivus' stock was up about 13 percent at $4.40 in afternoon trading.

  • Sept 18- An erectile dysfunction drug that reduces by half the time patients need to take the pill before sexual activity has been approved by the U.S. Food and Drug Administration.

  • US STOCKS-Wall St to open flat, eyes on Fed statement Wednesday, 17 Sep 2014 | 9:15 AM ET

    NEW YORK, Sept 17- U.S. stocks were set to open little changed on Wednesday ahead of a key statement by the Federal Reserve which is expected to provide clues on the next monetary policy move by the U.S. central bank.

  • NEW YORK, Sept 17- Auxilium Pharmaceuticals shares surged in brisk premarket trading Wednesday, a day after receiving an unsolicited offer from Endo International. Analysts said the offer could complicate Auxilium's buyout of Canadian eye drug maker QLT Inc, whose U.S. shares were down 11.3 percent in light trading.

  • Sept 17- Auxilium Pharmaceuticals Inc said it would not withdraw its offer to buy Canadian eye drug maker QLT Inc and adopted a poison pill, a day after receiving an unsolicited buyout offer from Endo International Plc.

  • Sept 17- Auxilium Pharmaceuticals Inc adopted a poison pill with a 15 percent trigger, a day after an unsolicited $2.2 billion buyout offer from Endo International Plc.

  • Sept 16- Endo International Plc made an unsolicited offer to buy Auxilium Pharmaceuticals Inc for about $2.2 billion, which analysts said could complicate Auxilium's buyout of Canadian eye drug maker QLT Inc.

  • Sept 16- Specialty healthcare company Endo International Plc offered to buy Auxilium Pharmaceuticals Inc for about $2.2 billion in cash and stock to expand its men's healthcare products business.

  • Endo offers to buy Auxilium Pharma for about $2.2 bln Tuesday, 16 Sep 2014 | 5:01 PM ET

    Sept 16- Endo International Plc offered to acquire Auxilium Pharmaceuticals Inc for about $2.2 billion in cash and stock. The offer of $28.10 per share represents a premium of 30.6 percent to Auxilium's Tuesday closing price of $21.52 on the Nasdaq. Endo said it intends to fund the transaction through cash on hand and debt financing.